{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123355","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.424604+00:00","generated_at":"2026-05-30T03:25:50.226250+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Assembly Bio reports Q3 net loss of $9.6M; positive Phase 1a data for ABI-5366","bullets":["Net loss of $9.6M ($1.51/share) vs $14.4M ($3.29/share) in Q3 2023; revenue of $6.8M from Gilead collaboration.","Cash $95.0M as of Sept 30, 2024, projected to fund operations into Q1 2026.","Positive Phase 1a interim data for ABI-5366 (HSV) supports once-weekly and once-monthly oral dosing; Phase 1b initiated.","Phase 1b trial for ABI-4334 (HBV) ongoing, interim data expected by end of 2024.","ABI-1179 and ABI-6250 on track to enter clinic by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123355","json":"https://secwatch.observer/filing/0000950170-24-123355.json","markdown":"https://secwatch.observer/filing/0000950170-24-123355.md","text":"https://secwatch.observer/filing/0000950170-24-123355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024123355/0000950170-24-123355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017024123355/asmb-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:25:50.226250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}